Oral contraception and the recognised gynaecological indications for such oestrogen-progestogen combinations. The decision to prescribe Logynon ED should take into consideration the individual woman's current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Logynon ED compares with other combined hormonal contraceptives (CHCs) (see sections 4.3 and 4.4).
Oral contraception and the recognised gynaecological indications for such oestrogen-progesterone combinations. The decision to prescribe Logynon should take into consideration the individual woman's current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Logynon compares with other combined hormonal contraceptives (CHCs) (see sections 4.3 and 4.4).
Acute heart failure (AHF) is a leading cause of admission in emergency departments (ED).
Objective: To assess the prevalence of obstructive sleep apnoea (OSA) in men presenting with erectile dysfunction (ED) at a single centre.
Background and aim: Secondary loss of response to adalimumab (ADA-LOR) commonly occurs in patients with Crohn's disease (CD) treated with adalimumab (ADA).
Emerging neuromodulation devices show promise for expanding acute treatment options. Over the past few years, there has been a growth in research investigating the efficacy and safety of non-invasive neuromodulation, which delivers electrical or magnetic stimulation to nerves or neural tissue, for the management of acute attacks of migraine
Results from a new study presented in an oral presentation at the Annual European Congress of Rheumatology (EULAR 2018) show...
Vivus, Inc. announced that the European Commission (EC) has adopted the implementing decision granting marketing authorization for Spedra (avanafil) for...
A recent survey questions the ability of digital assistants to answer sex- and sexual health-related questions.
Oral contraception and the recognised gynaecological indications for such oestrogen progestogen combinations. The decision to prescribe Femodene ED should take into consideration the individual woman's current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Femodene ED compares with other combined hormonal contraceptives (CHCs) (see sections 4.3 and 4.4).